Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
There is a new appreciation of the perimenopause – defined as the early and late menopause transition stages as well as the early postmenopause - as a window of vulnerability for the development of both depressive symptoms and major depressive episodes. However, clinical recommendations on how to identify, characterize and treat clinical depression are lacking. To address this gap, an expert panel was convened to systematically review the published literature and develop guidelines on the evaluation and management of perimenopausal depression. The areas addressed included: 1) epidemiology; 2) clinical presentation; 3) therapeutic effects of antidepressants; 4) effects of hormone therapy; and 5) efficacy of other therapies (eg, psychotherapy, exercise, and natural health products). Overall, evidence generally suggests that most midlife women who experience a major depressive episode during the perimenopause have experienced a prior episode of depression. Midlife depression presents with classic depressive symptoms commonly in combination with menopause symptoms (ie, vasomotor symptoms, sleep disturbance), and psychosocial challenges. Menopause symptoms complicate, co-occur, and overlap with the presentation of depression. Diagnosis involves identification of menopausal stage, assessment of co-occurring psychiatric and menopause symptoms, appreciation of the psychosocial factors common in midlife, differential diagnoses, and the use of validated screening instruments. Proven therapeutic options for depression (ie, antidepressants, psychotherapy) are the front-line treatments for perimenopausal depression. Although estrogen therapy is not approved to treat perimenopausal depression, there is evidence that it has antidepressant effects in perimenopausal women, particularly those with concomitant vasomotor symptoms. Data on estrogen plus progestin are sparse and inconclusive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., McMurdo, M., & Mead, G. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004366.pub6 · Cited by 1,834
Prevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Prevalence, incidence and stability of premenstrual dysphoric disorder in the community
WITTCHEN, H.-U., BECKER, E., LIEB, R., & KRAUSE, P. (2002) · Psychological Medicine · doi:10.1017/s0033291701004925 · Cited by 554
Lynch, D., Laws, K. R., & McKenna, P. J. (2010) · Psychological Medicine · doi:10.1017/s003329170900590x · Cited by 317
Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions
Thase, M. E., Entsuah, R., Cantillon, M., & Kornstein, S. G. (2005) · Journal of Women s Health · doi:10.1089/jwh.2005.14.609 · Cited by 201
Self-citationWeitz, E. S., Hollon, S. D., Twisk, J., van Straten, A., Huibers, M. J. H., David, D., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W., Cristea, I. A., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.1516 · Cited by 187
Reilly, T. J., MacGillivray, S. A., Reid, I. C., & Cameron, I. M. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.09.008 · Cited by 155
Twomey, C., O’Reilly, G., & Byrne, M. (2015) · Family Practice · doi:10.1093/fampra/cmu060 · Cited by 123
Pérez-López, F. R., Martínez-Domínguez, S. J., Lajusticia, H., & Chedraui, P. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.09.001 · Cited by 108
Cited by
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Self-citationMalhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
Hormonal Contraceptives and Mood: Review of the Literature and Implications for Future Research
Robakis, T., Williams, K. E., Nutkiewicz, L., & Rasgon, N. L. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1034-z · Cited by 103
Williams, E. S., Manning, C. E., Eagle, A. L., Swift-Gallant, A., Duque-Wilckens, N., Chinnusamy, S., Moeser, A., Jordan, C., Leinninger, G., & Robison, A. J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.08.006 · Cited by 101
Liang, G., Kow, A. S. F., Yusof, R., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2024) · Biomedicines · doi:10.3390/biomedicines12010184 · Cited by 68
“…classes: tricyclic antidepressants (e.g., Clomipramine, amitriptyline, doxepin), monoamine oxidase inhibitors (e.g., Phenylethylhydrazine, bromo-faromine, toloxadone, isozohydrazine), and selective serotonin reuptake inhibitors (e.g., fluoxetine, citalopram, escitalopram, sertraline) [18–20].”
Metadata
- Authors
- Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H. K., Cohen, L. S., & Soares, C. N.
- Venue
- Menopause
- Published
- 2018-10
- Volume
- 25
- Issue
- 10
- Pages
- 1069-1085
- ISSN
- 1072-3714 (ISSN-L)
- 1530-0374
- OpenAlex
- W2888993981
- Cited by
- 250
- References
- 11
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. https://app.cochat.ai/papers/10.1097/gme.0000000000001174
- The paper
- Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H. K., Cohen, L. S., & Soares, C. N. (2018). Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. https://doi.org/10.1097/gme.0000000000001174
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.